View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 22, 2021

Todos Medical concludes enrolment in Phase II oral drug trial for Covid-19

The DSMB is expected to evaluate the interim analysis data from the trial in the fourth quarter of this year.

Todos Medical, along with its partner, NLC Pharma, has concluded subject enrolment to carry out an interim assessment of the Phase II clinical trial of oral antiviral drug, Tollovir, in severe and critical Covid-19 patients who are in hospital.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The enrolment was halted temporarily at two open trial centres in Israel to carry out the interim analysis of the trial data.

An inhibitor of 3CL protease (3CLpro), Tollovir is an anti-cytokine treatment candidate for the nidovirus subgroup of coronaviruses such as SARS-CoV-2, SARS-CoV-1, MERS and 229E.

Developed from completely natural components, the drug can potentially guarantee robust in vitro hindering of 3CLpro and anti-cytokine activity.

The randomised, placebo-controlled, double-blind trial will enrol a total of 77 subjects hospitalised with Covid-19.

The decline in time spent in the hospital and time to clinical improvement will be the primary goals of the trial.

Mortality, occurrence and time spent on supplemental oxygen, the incidence of worsening and the requirement for mechanical ventilation will be the secondary goals.

If subjects required intubation during or following enrolment, Tollovir is given through a feeding tube to progress the treatment.

The Data Safety and Monitoring Board (DSMB) of the trial is anticipated to analyse the interim analysis data in the fourth quarter of this year.

Todos noted that the interim analysis was earlier planned to be conducted on 33 subjects but will now be carried out on the 31 subjects enrolled as of 10 November.

This move is based on the statistician’s advice using blinded data that demonstrated that the trial could have met the threshold needed for futility assessment.

On concluding the interim analysis, Todos will decide on further steps to clinically advance Tollovir for Covid-19 in various groups of people who are admitted to the hospital, have a moderate disease, are long haulers and are aged below 18 years.

Todos Medical president and CEO Gerald Commissiong said: “If the interim results resemble the observational study, demonstrating a significant reduction of time in the hospital and death, it will cement the direction of our clinical trial pathway.

“We believe Tollovir could become a highly sought-after therapeutic candidate in the hospitalised setting which represents patients at the highest risk of death and the highest cost of care.”

In April, the company commenced the Phase II trial to assess the safety and efficacy of Tollovir for the treatment of Covid-19 patients in the hospital.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU